NEW YORK, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ:PSEC) announced today that Prospect has purchased $32 million of first lien senior secured floating rate notes issued by AgaMatrix, Inc.
Headquartered in Salem, New Hampshire, AgaMatrix is a leading developer, manufacturer, and marketer of innovative diabetes care solutions for blood glucose monitoring and data management on mobile and cloud platforms. AgaMatrix’s products are powered by the company’s proprietary and patent-protected technologies. The Diabetes Technology Society recently recognized AgaMatrix products for their high quality of accuracy relative to competing products in the marketplace.
“The Prospect team has deep experience in the healthcare sector and worked with our company to provide a customized solution for our particular financing needs,” said John Alberico, President and Chief Executive Officer of AgaMatrix. “We found Prospect to be a highly collaborative organization throughout the transaction process.”
“Prospect is pleased to support AgaMatrix and its continued growth in the blood glucose monitoring industry,” said David Moszer, Managing Director of Prospect Capital Management L.P. “AgaMatrix offers affordable products that are among the highest accuracy within the industry, helping millions of patients monitor their health on a daily basis.”
ABOUT PROSPECT CAPITAL CORPORATION
Prospect Capital Corporation (www.prospectstreet.com) is a business development company that focuses on lending to and investing in private businesses. Prospect’s investment objective is to generate both current income and long-term capital appreciation through debt and equity investments.
Prospect has elected to be treated as a business development company under the Investment Company Act of 1940 (“1940 Act”). Prospect is required to comply with a series of regulatory requirements under the 1940 Act as well as applicable NASDAQ, federal and state rules and regulations. Prospect has elected to be treated as a regulated investment company under the Internal Revenue Code of 1986. Failure to comply with any of the laws and regulations that apply to Prospect could have an adverse effect on Prospect and its shareholders.